TY - JOUR
T1 - Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico
AU - Amaya-Larios, Irma Y.
AU - Martínez-Vega, Ruth Aralí
AU - Mayer, Sandra V.
AU - Galeana-Hernández, Marisol
AU - Comas-García, Andreu
AU - Sepúlveda-Salinas, Karla J.
AU - Falcón-Lezama, Jorge A.
AU - Vasilakis, Nikos
AU - Ramos-Castañeda, José
N1 - Publisher Copyright:
Copyright © 2014 by The American Society of Tropical Medicine and Hygiene.
PY - 2014/11/1
Y1 - 2014/11/1
N2 - Humoral immune response against dengue virus (DENV) is an important component in dengue-endemic transmission. We conducted a cross-sectional nested cohort study to determine the seroprevalence and frequency of neutralizing antibodies against DENV serotypes in two endemic localities in the state of Morelos, Mexico. The cohort participants (N = 1,196) were screened to determine previous exposure to DENV. Overall seroprevalence was 76.6% (95% confidence interval [95% CI] = 73.6-79.2), and prevalence of neutralizing antibodies in the 5- to 9-year-old group was 82.5% (95% CI = 67.2-92.7), 45% (95% CI = 29.3-61.5), and 65% (95% CI = 48.3-79.4) for DENV-1, DENV-2, and DENV-3, respectively. For participants older than 10 years, the observed seroprevalence was above 60% for each serotype, except DENV-4 in the 10- to 25-year-old group (42.9%); 81% of humoral responses were multitypic. The outcomes of our study contribute to understanding the immune component of dengue transmission and provide focal information for the evaluation of vaccine candidates under development.
AB - Humoral immune response against dengue virus (DENV) is an important component in dengue-endemic transmission. We conducted a cross-sectional nested cohort study to determine the seroprevalence and frequency of neutralizing antibodies against DENV serotypes in two endemic localities in the state of Morelos, Mexico. The cohort participants (N = 1,196) were screened to determine previous exposure to DENV. Overall seroprevalence was 76.6% (95% confidence interval [95% CI] = 73.6-79.2), and prevalence of neutralizing antibodies in the 5- to 9-year-old group was 82.5% (95% CI = 67.2-92.7), 45% (95% CI = 29.3-61.5), and 65% (95% CI = 48.3-79.4) for DENV-1, DENV-2, and DENV-3, respectively. For participants older than 10 years, the observed seroprevalence was above 60% for each serotype, except DENV-4 in the 10- to 25-year-old group (42.9%); 81% of humoral responses were multitypic. The outcomes of our study contribute to understanding the immune component of dengue transmission and provide focal information for the evaluation of vaccine candidates under development.
UR - http://www.scopus.com/inward/record.url?scp=84910647990&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84910647990&partnerID=8YFLogxK
U2 - 10.4269/ajtmh.14-0145
DO - 10.4269/ajtmh.14-0145
M3 - Review article
C2 - 25294613
AN - SCOPUS:84910647990
SN - 0002-9637
VL - 91
SP - 1057
EP - 1065
JO - American Journal of Tropical Medicine and Hygiene
JF - American Journal of Tropical Medicine and Hygiene
IS - 5
ER -